A Novel Prognostic Model of NPI for Risk-Predicting and Clinical Decision-making in Diffuse Large B-Cell Lymphoma in the Rituximab Era
NCT04624971
·
clinicaltrials.gov ↗
UNKNOWN
Status
2000
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma
Sponsor
Sun Yat-sen University